Interferon-alpha2 variants
Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera
Key Facts
About Heligenics
Heligenics is a private, pre-revenue biotech platform company pioneering a genetics-inspired approach to biologic drug discovery. Its core innovation is the GigaAssay™, a high-throughput, cell-based screening platform capable of analyzing hundreds of thousands of biologic variants simultaneously to map function and identify optimized drug candidates. The company has generated a substantial preclinical pipeline focused on interferon biobetters for autoimmune diseases and cancer, and is actively developing GLP-1 variants for the metabolic disorder space. Heligenics operates primarily through partnerships with pharmaceutical and biotechnology companies to advance and license its discovered assets.
View full company profile